Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

CaM I Inhibitors

Calmodulin (CaM) I inhibitors represent a class of chemical compounds that interact with calmodulin, a pivotal intracellular calcium-binding protein, to modulate various cellular processes. CaM, a ubiquitous and highly conserved protein, acts as a vital mediator in calcium-dependent signal transduction pathways. It plays a critical role in transducing calcium signals into diverse cellular responses, ranging from muscle contraction to neuronal signaling. CaM I inhibitors exert their effects by binding to specific domains on calmodulin, perturbing its ability to interact with downstream effector proteins. This interaction effectively disrupts the intricate calcium-dependent regulatory mechanisms that calmodulin orchestrates. Structurally, CaM I inhibitors often possess distinct motifs that allow them to interface with the hydrophobic binding pockets on calmodulin. These pockets are responsible for binding to target proteins in a calcium-dependent manner. By obstructing the access of calmodulin to its target partners, these inhibitors hinder downstream signaling cascades that are crucial for various cellular functions. CaM I inhibitors exhibit specificity towards certain isoforms of calmodulin, adding a layer of selectivity to their action. The inhibition of calmodulin by this class of compounds has been extensively studied to elucidate the underlying molecular mechanisms. Inhibition often involves complex conformational changes in calmodulin's structure, altering its affinity for both calcium ions and effector proteins. This leads to a disruption of protein-protein interactions that depend on calmodulin's calcium-bound state. In essence, CaM I inhibitors act as molecular switches, manipulating calmodulin's regulatory role in transmitting calcium signals. Studying these inhibitors has not only provided insights into calmodulin's intricate functioning but has also contributed to our understanding of calcium-mediated cellular responses. In sum, the exploration of CaM I inhibitors illuminates the sophisticated interplay between calcium signaling and downstream cellular processes, offering potential avenues for further mechanistic investigations.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

BCR-ABL kinase inhibitor used for certain leukemias.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

EGFR kinase inhibitor targeting non-small cell lung cancer.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$240.00
$1030.00
7
(1)

Androgen receptor inhibitor for advanced prostate cancer.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

JAK1/2 inhibitor approved for myelofibrosis and polycythemia.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

BTK inhibitor with applications in B cell malignancies.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Multikinase inhibitor targeting RAF, VEGFR, PDGFR, etc.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$206.00
$299.00
$485.00
10
(1)

PARP inhibitor disrupting DNA repair, particularly in BRCA-mutated cancers.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$116.00
$330.00
$510.00
$816.00
$1632.00
10
(0)

BCL-2 inhibitor promoting apoptosis in various cancers.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

mTOR inhibitor impeding cell growth and proliferation.